Biostage, Inc. entered into securities purchase agreements with certain investors in a private placement an aggregate of 1,000,967 common shares at a price of $6 per share for the gross proceeds of $6.005802 million on March 31, 2023.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | +6.52% | +5.60% | -50.90% |
1st Jan change | Capi. | |
---|---|---|
-50.90% | 35.07M | |
+11.62% | 225B | |
+15.80% | 197B | |
+19.30% | 143B | |
+30.57% | 111B | |
+2.62% | 64.72B | |
+18.88% | 54.44B | |
+4.96% | 51.06B | |
+10.38% | 45.03B | |
+4.70% | 37.4B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. announced that it expects to receive $6.005802 million in funding